Therapy of recalcitrant macular edema in aphakic and/or eyes with with severe iris-lens diaphragm disruption with longterm intravitreal steroid implants such as Iluvien® or Ozurdex®.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00020282

Enrollment

Registered

2019-12-23

Start date

2020-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recalcitrant macular edema H35.8

Interventions

Group 1: Sclerale Fixation of an intravitreal steroid implant

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. chronic macular edema 2. postoperative cystoid macular edema (Irvine Gass-Syndrom) 3. History of migrationof an implantats into the anterior chamber or high Risk of migration 4. History of complications after Ozurdex®-Implantation 5. functional worse eye 6. Central retinal thickness of 500µm or more

Exclusion criteria

Exclusion criteria: Glaucoma

Design outcomes

Primary

Measure	Time frame
Best corrected Visual Acuity (BCVA) after 12, 24 and 36 months postoperatively.	—

Secondary

Measure	Time frame
Reduction of central retinal thickness (SD-OCT)	—

Countries

Germany

Contacts

Public ContactArmin Wolf

Augenklinik des Klnikums der Ludwig-Maximilians-Universität München

armin.wolf@med.uni-muenchen.de0049 89 4400 53743

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026